Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 92INDUSTRY 27NIH 10NETWORK 2INDIV 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Proflavine 9Microbial Collagenase 2plerixafor 1pembrolizumab 1pegfilgrastim 1olaparib 1nilotinib 1macimorelin 1keyhole-limpet hemocyanin 1ethyl pyruvate 1compound W 1blinatumomab 1Uracil 1Tegafur 1Surgical Procedures, Operative 1Sodium Chloride 1Sirolimus 1Salicylates 1Peptides 1PM 01183 1Monatide (IMS 3015) 1Mifepristone 1Gemcitabine 1Fluorescein 1Everolimus 1Doxorubicin 1Darbepoetin alfa 1Curettage 1Corlux 1Circumcision, Male 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDIV × Interventional × blinatumomab × Clear all
NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡